Tempus AI

SoftBank Group has partnered with Tempus AI to form a new joint venture that aims to use artificial intelligence (AI) to analyze personal medical data and provide treatment recommendations. SoftBank Group CEO Masayoshi Son announced the news at a press conference in Tokyo. This is the latest move by SoftBank after announcing a series of artificial intelligence investments, marking a step-up in SoftBank's investment pace after several years of sluggish investment activity. SoftBank invested about $200 million in Tempus' G round of financing in April this year, and Tempus subsequently went public on the Nasdaq in June. Tempus…

Tempus AI is a diagnostics company that uses artificial intelligence (AI) to interpret medical tests, aiming to help doctors provide more accurate treatment options for patients. On Friday, the company debuted on the Nasdaq under the ticker “TEM”, and its stock price rose as much as 15% after the opening. Tempus AI issued 11.1 million shares at $37 per share on Thursday, at the high end of its initial target range of $35 to $37. The company raised $410 million through the IPO, with a total valuation of more than $6 billion. Although the stock price rose in early trading…